Silo Pharma Announces Positive Results in Alzheimer’s Disease Study
January 24 2024 - 8:55AM
Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or “the Company”), a
biopharmaceutical company developing novel formulations and drug
delivery systems for traditional therapeutics and psychedelic
treatments, today announced that its Alzheimer’s disease
therapeutic SPC-14 showed positive efficacy in small animals.
Data from a study conducted at Columbia University in
collaboration with Silo Pharma showed that SPC-14 was effective
against LH stress in attenuating learned helplessness,
perseverative behavior, and hyponeophagia (a measure of anxiety).
The mice were treated twice daily with the SPC-14 therapeutic.
“We believe that today's announcement, along with our past
studies of SPC-14 conducted in female rodents, lends credibility to
our discovery of a therapeutic that could bring relief to patients
and families suffering from Alzheimer’s disease, a debilitating
disease that degrades cognitive function and can erase a lifetime
of memories. We look forward to updating our shareholders on the
next steps and data needed to advance SPC-14 to a clinical study,”
stated Eric Weisblum, Chief Executive Officer of Silo Pharma.
About Silo Pharma Silo Pharma Inc.
(Nasdaq: SILO) is a developmental stage biopharmaceutical company
developing novel therapeutics that address underserved conditions
including stress-induced psychiatric disorders, chronic pain
conditions, and central nervous system (CNS) diseases. Silo focuses
on developing traditional therapies and psychedelic treatments in
novel formulations and drug delivery systems. The Company’s lead
program, SPC-15, is an intranasal treatment targeting PTSD and
stress-induced anxiety disorders. SP-26 is a time-release
ketamine-loaded implant for fibromyalgia and chronic pain relief.
Silo’s two preclinical programs are SPC-14, an intranasal compound
for the treatment of Alzheimer’s disease, and SPU-16, a CNS-homing
peptide targeting multiple sclerosis (MS). Silo’s research and
development programs are conducted through collaborations with
Columbia University and the University of Maryland, Baltimore. For
more information, visit www.silopharma.com and connect on
social media at LinkedIn, X, and Facebook.
Forward-Looking Statements This news
release contains "forward-looking statements" within the meaning of
the “safe harbor” provisions of the Private Securities Litigation
Reform Act of 1995. These statements are identified by the use of
words “could”, “believe”, “anticipate”, “intend”, “estimate”,
“expect”, “may”, “continue”, “predict”, “potential”, and similar
expressions that are intended to identify forward-looking
statements. Such statements involve known and unknown risks,
uncertainties, and other factors that could cause the actual
results of Silo Pharma, Inc. (“Silo” or “the Company”) to differ
materially from the results expressed or implied by such
statements, including changes to anticipated sources of revenues,
future economic and competitive conditions, difficulties in
developing the Company’s technology platforms, retaining and
expanding the Company’s customer base, fluctuations in consumer
spending on the Company’s products and other factors. Accordingly,
although the Company believes that the expectations reflected in
such forward-looking statements are reasonable, there can be no
assurance that such expectations will prove to be correct. The
Company disclaims any obligations to publicly update or release any
revisions to the forward-looking information contained in this
presentation, whether as a result of new information, future
events, or otherwise, after the date of this presentation or to
reflect the occurrence of unanticipated events except as required
by law.
Contact 800-705-0120
investors@silopharma.com
Silo Pharma (NASDAQ:SILO)
Historical Stock Chart
From Apr 2024 to May 2024
Silo Pharma (NASDAQ:SILO)
Historical Stock Chart
From May 2023 to May 2024